Literature DB >> 8664388

Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database.

D S Raiford1, S Pérez Gutthann, L A García Rodríguez.   

Abstract

We examined the positive predictive value of the International Classification of Diseases, 9th revision (ICD-9), codes used to identify cases of complicated peptic ulcer disease from the Saskatchewan Hospital automated database. Nonspecific and site- and lesion-specific codes were used in case detection to increase the sensitivity of the initial computer search. Review of the hospital records of 1,762 potential cases resulted in 1,375 confirmed cases. The positive predictive value of site and lesion-specific codes was about 90% and was about 70% for the nonspecific codes. Almost 50% of cases, however, would have been missed if the nonspecific codes had not been used.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8664388     DOI: 10.1097/00001648-199601000-00018

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  30 in total

1.  Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

Authors:  Peter M Wahl; Joshua J Gagne; Thomas E Wasser; Debra F Eisenberg; J Keith Rodgers; Gregory W Daniel; Marcus Wilson; Sebastian Schneeweiss; Jeremy A Rassen; Amanda R Patrick; Jerry Avorn; Rhonda L Bohn
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications.

Authors:  E Garbe; S Kloss; M Suling; I Pigeot; S Schneeweiss
Journal:  Eur J Clin Pharmacol       Date:  2012-07-05       Impact factor: 2.953

3.  Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable.

Authors:  M Alan Brookhart; Philip S Wang; Daniel H Solomon; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2006-05       Impact factor: 4.822

4.  Comparative gastrointestinal safety of weekly oral bisphosphonates.

Authors:  S M Cadarette; J N Katz; M A Brookhart; T Stürmer; M R Stedman; R Levin; D H Solomon
Journal:  Osteoporos Int       Date:  2009-03-06       Impact factor: 4.507

5.  Secular trends in the survival of patients with laryngeal carcinoma, 1995-2007.

Authors:  S D MacNeil; K Liu; S Z Shariff; A Thind; E Winquist; J Yoo; A Nichols; K Fung; S Hall; A X Garg
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

6.  Comment on: "Desideratum for evidence-based epidemiology".

Authors:  Sean Hennessy; Charles E Leonard
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

7.  The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies.

Authors:  Elisabetta Patorno; Joshua J Gagne; Christine Y Lu; Kevin Haynes; Andrew T Sterrett; Jason Roy; Xingmei Wang; Marsha A Raebel
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

8.  Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

Authors:  Muhammad Mamdani; Paula A Rochon; David N Juurlink; Alex Kopp; Geoffrey M Anderson; Gary Naglie; Peter C Austin; Andreas Laupacis
Journal:  BMJ       Date:  2002-09-21

9.  Adverse gastrointestinal events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.

Authors:  Robert J Campbell; Chaim M Bell; Susan E Bronskill; J Michael Paterson; Marlo Whitehead; Erica de L Campbell; Sudeep S Gill
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

10.  Can health care databases be used to identify incident cases of osteonecrosis?

Authors:  Steven C Vlad; David T Felson; Donald R Miller
Journal:  Arthritis Res Ther       Date:  2009-06-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.